On Monday, Novavax, Inc (NASDAQ: NVAX) opened higher 1.08% from the last session, before settling in for the closing price of $9.22. Price fluctuations for NVAX have ranged from $3.53 to $23.86 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 653.01% annually for the last half of the decade. Company’s average yearly earnings per share was noted 76.43% at the time writing. With a float of $152.99 million, this company’s outstanding shares have now reached $160.15 million.
In an organization with 1543 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 66.75%, operating margin of -33.36%, and the pretax margin is -31.6%.
Novavax, Inc (NVAX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Novavax, Inc is 4.49%, while institutional ownership is 59.84%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,435. In this transaction Director of this company sold 4,150 shares at a rate of $9.02, taking the stock ownership to the 14,770 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director sold 5,400 for $8.00, making the entire transaction worth $43,200. This insider now owns 51,760 shares in total.
Novavax, Inc (NVAX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.43% per share during the next fiscal year.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Check out the current performance indicators for Novavax, Inc (NVAX). In the past quarter, the stock posted a quick ratio of 0.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.26, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Let’s dig in a bit further. During the last 5-days, its volume was 4.08 million. That was inferior than the volume of 5.17 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.31%. Additionally, its Average True Range was 0.64.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 29.85%, which indicates a significant decrease from 30.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.36% in the past 14 days, which was higher than the 81.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.67, while its 200-day Moving Average is $10.95. However, in the short run, Novavax, Inc’s stock first resistance to watch stands at $9.60. Second resistance stands at $9.89. The third major resistance level sits at $10.14. If the price goes on to break the first support level at $9.06, it is likely to go to the next support level at $8.81. Assuming the price breaks the second support level, the third support level stands at $8.52.
Novavax, Inc (NASDAQ: NVAX) Key Stats
There are currently 160,185K shares outstanding in the company with a market cap of 1.49 billion. Presently, the company’s annual sales total 983,710 K according to its annual income of -545,060 K. Last quarter, the company’s sales amounted to 84,510 K and its income totaled -121,300 K.
